Related Experiment Video
Updated: May 7, 2026
07:55
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
13.7K
Soft Tissue Sarcoma Burden and Research Productivity: Global Patterns and Disparities, 1990-2021.
Hongjie Pan1,2, Ping Tao3, Hongfei Zhu4
1Department of General Surgery, First Affiliated Hospital Anhui University of Science and Technology Huainan Anhui Province China.
Health Science Reports
|May 6, 2026
Summary
Soft tissue sarcoma (STS) burden remained stable globally from 1990-2021, with geographic disparities. Research investment increased, yet effective treatments for this rare cancer are still limited.
Area of Science:
- Oncology
- Epidemiology
- Global Health
Background:
- Soft tissue sarcoma (STS) is a rare and diverse cancer with limited global epidemiological data.
- Disproportionate incidence and impact necessitate comprehensive global studies.
Purpose of the Study:
- To analyze long-term global burden trends of STS from 1990 to 2021.
- To investigate epidemiological features and global research productivity in STS.
Main Methods:
- Utilized 2021 Global Burden of Disease (GBD) Study data for incidence, prevalence, mortality, and DALYs.
- Employed joinpoint and age-period-cohort (APC) analyses for trend assessment.
- Assessed research productivity via funding, scientific output, drug development, and clinical trials.
Main Results:
- In 2021, STS accounted for 96,201 cases and 50,203 deaths globally.
- Age-standardized incidence was 1.16/100,000, mortality 20.54/100,000.
- Higher incidence in high-HDI countries; mortality doubled in low-HDI countries. Research productivity increased, but treatments remain limited.
Conclusions:
- Global STS burden remained stable with significant geographic disparities.
- Increased global investment in STS research, but therapeutic options are still insufficient.
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
5.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.2K
01:03Rous Sarcoma Virus (RSV) and Cancer
5.2K
5.2K
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
01:21Cancer Survival Analysis
870
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
870